A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

  • Interventional
  • Recruiting
  • NCT04229004

Precision Promise Platform Trial for Metastatic Pancreatic Cancer

Precision Promise is a multi-center, seamless Phase 2/3 platform trial designed to evaluate multiple regimens in metastatic pancreatic cancer. Primary Objectives - To compare each investigational arm versus standard of care (SOC) for superiority in overall survival in first and/or second line metastatic ductal adenocarcinoma (metastatic pancreatic cancer) participants and determine which, if any, participants benefit from each investigational arm. Secondary Objectives - To determine short and long-term safety signals of each investigational arm in metastatic pancreatic cancer participants vs. SOC. - To determine progression-free survival (PFS) for each investigational arm vs. SOC. - To determine rates of overall response, CR, and PR; duration of overall response, CR or PR (whichever occurs first). - To determine rates of clinical benefit; duration of clinical benefit.